Karin Dembrower1, Erik Wåhlin2, Yue Liu3, Mattie Salim4, Kevin Smith3, Peter Lindholm5, Martin Eklund6, Fredrik Strand7. 1. Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden; Department of Radiology, Capio Sankt Görans Hospital, Stockholm, Sweden. Electronic address: karin.dembrower@ki.se. 2. Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden. 3. Department of Computational Science and Technology, KTH Royal Institute of Technology and Science for Life Laboratory, Stockholm, Sweden. 4. Department of Pathology and Oncology, Karolinska Institute, Stockholm, Sweden; Department of Radiology, Karolinska University Hospital, Stockholm, Sweden. 5. Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. 6. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. 7. Department of Pathology and Oncology, Karolinska Institute, Stockholm, Sweden; Breast Radiology, Karolinska University Hospital, Stockholm, Sweden.
Abstract
BACKGROUND: We examined the potential change in cancer detection when using an artificial intelligence (AI) cancer-detection software to triage certain screening examinations into a no radiologist work stream, and then after regular radiologist assessment of the remainder, triage certain screening examinations into an enhanced assessment work stream. The purpose of enhanced assessment was to simulate selection of women for more sensitive screening promoting early detection of cancers that would otherwise be diagnosed as interval cancers or as next-round screen-detected cancers. The aim of the study was to examine how AI could reduce radiologist workload and increase cancer detection. METHODS: In this retrospective simulation study, all women diagnosed with breast cancer who attended two consecutive screening rounds were included. Healthy women were randomly sampled from the same cohort; their observations were given elevated weight to mimic a frequency of 0·7% incident cancer per screening interval. Based on the prediction score from a commercially available AI cancer detector, various cutoff points for the decision to channel women to the two new work streams were examined in terms of missed and additionally detected cancer. FINDINGS: 7364 women were included in the study sample: 547 were diagnosed with breast cancer and 6817 were healthy controls. When including 60%, 70%, or 80% of women with the lowest AI scores in the no radiologist stream, the proportion of screen-detected cancers that would have been missed were 0, 0·3% (95% CI 0·0-4·3), or 2·6% (1·1-5·4), respectively. When including 1% or 5% of women with the highest AI scores in the enhanced assessment stream, the potential additional cancer detection was 24 (12%) or 53 (27%) of 200 subsequent interval cancers, respectively, and 48 (14%) or 121 (35%) of 347 next-round screen-detected cancers, respectively. INTERPRETATION: Using a commercial AI cancer detector to triage mammograms into no radiologist assessment and enhanced assessment could potentially reduce radiologist workload by more than half, and pre-emptively detect a substantial proportion of cancers otherwise diagnosed later. FUNDING: Stockholm City Council.
BACKGROUND: We examined the potential change in cancer detection when using an artificial intelligence (AI) cancer-detection software to triage certain screening examinations into a no radiologist work stream, and then after regular radiologist assessment of the remainder, triage certain screening examinations into an enhanced assessment work stream. The purpose of enhanced assessment was to simulate selection of women for more sensitive screening promoting early detection of cancers that would otherwise be diagnosed as interval cancers or as next-round screen-detected cancers. The aim of the study was to examine how AI could reduce radiologist workload and increase cancer detection. METHODS: In this retrospective simulation study, all women diagnosed with breast cancer who attended two consecutive screening rounds were included. Healthy women were randomly sampled from the same cohort; their observations were given elevated weight to mimic a frequency of 0·7% incident cancer per screening interval. Based on the prediction score from a commercially available AI cancer detector, various cutoff points for the decision to channel women to the two new work streams were examined in terms of missed and additionally detected cancer. FINDINGS: 7364 women were included in the study sample: 547 were diagnosed with breast cancer and 6817 were healthy controls. When including 60%, 70%, or 80% of women with the lowest AI scores in the no radiologist stream, the proportion of screen-detected cancers that would have been missed were 0, 0·3% (95% CI 0·0-4·3), or 2·6% (1·1-5·4), respectively. When including 1% or 5% of women with the highest AI scores in the enhanced assessment stream, the potential additional cancer detection was 24 (12%) or 53 (27%) of 200 subsequent interval cancers, respectively, and 48 (14%) or 121 (35%) of 347 next-round screen-detected cancers, respectively. INTERPRETATION: Using a commercial AI cancer detector to triage mammograms into no radiologist assessment and enhanced assessment could potentially reduce radiologist workload by more than half, and pre-emptively detect a substantial proportion of cancers otherwise diagnosed later. FUNDING: Stockholm City Council.
Authors: Sarah E Hickman; Ramona Woitek; Elizabeth Phuong Vi Le; Yu Ri Im; Carina Mouritsen Luxhøj; Angelica I Aviles-Rivero; Gabrielle C Baxter; James W MacKay; Fiona J Gilbert Journal: Radiology Date: 2021-10-19 Impact factor: 11.105
Authors: Marthe Larsen; Camilla F Aglen; Christoph I Lee; Solveig R Hoff; Håkon Lund-Hanssen; Kristina Lång; Jan F Nygård; Giske Ursin; Solveig Hofvind Journal: Radiology Date: 2022-03-29 Impact factor: 29.146
Authors: Anna W Anderson; M Luke Marinovich; Nehmat Houssami; Kathryn P Lowry; Joann G Elmore; Diana S M Buist; Solveig Hofvind; Christoph I Lee Journal: J Am Coll Radiol Date: 2022-01-20 Impact factor: 5.532
Authors: Karoline Freeman; Julia Geppert; Chris Stinton; Daniel Todkill; Samantha Johnson; Aileen Clarke; Sian Taylor-Phillips Journal: BMJ Date: 2021-09-01